Scientific Reports
October 6, 2023
Junliang Zhang, Zhongzheng Hu, Shuang Zheng et al.
11 citations
The study aims to explore the relationship among mindfulness, depression, meaning in life (MIL) and psychological resilience (PR), and verify whether MIL and PR have a chain mediating effect between mindfulness and depression. 1034 college students in a province were investigated by using Adolescent Mindfulness Scale, Depression Scale, Meaning in Life Scale and Psychological Resilience Scale....
Pilot and Feasibility Studies
October 5, 2023
Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner et al.
23 citations
Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (LSD) and...
New England Journal of Medicine
October 4, 2023
Andreas Reif, Istvan Bitter, Jozefien Buyze et al.
197 citations
BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with...
Expert Opinion on Investigational Drugs
October 3, 2023
Zofia Kozak, Matthew W Johnson, Scott T Aaronson
10 citations
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Expert Opinion on Emerging Drugs
October 2, 2023
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek et al.
4 citations
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to...
CPT: Pharmacometrics & Systems Pharmacology
October 2023
Marije E. Otto, Kirsten R Bergmann, Marieke L De Kam et al.
In clinical trials, Montgomery-Åsberg Depression Rating Scale (MADRS) questionnaire data are added up to total scores before analysis, assuming equal contribution of each separate question. Item Response Theory (IRT)-based analysis avoids this by using individual question responses to determine the latent variable (ψ), which represents a measure of depression severity. However, utilization of...
Brain, Behavior, and Immunity
October 1, 2023
Xinying Zhang, Teng He, Zifeng Wu et al.
CD38 is involved in immune responses, cell proliferation, and has been identified in the brain, where it is implicated in inflammation processes and psychiatric disorders. We hypothesized that dysfunctional CD38 activity in the brain may contribute to the pathogenesis of depression. To investigate the underlying mechanisms, we used a lipopolysaccharide (LPS)-induced depression model and...
CNS Drugs
October 1, 2023
Dania Akbar, Taeho Greg Rhee, Felicia Ceban et al.
A significant proportion of adults with major depressive disorder (MDD) do not respond to treatments which are currently used in clinical practice such as first-generation monoamine-based antidepressants. The objective of this systematic review was to assess the efficacy, safety, and mechanisms of action of AXS-05, a combination of the NMDA-receptor antagonist dextromethorphan with bupropion,...
Psychopharmacology
October 1, 2023
Youjia Qiu, Longyuan Li, Aojie Duan et al.
Nitrous oxide (N2O) has been initially confirmed by clinical trials to benefit to patients with major depressive disorder (MDD). However, there needs to be a meta-analysis to compare the efficacy and tolerability of N2O in MDD. PubMed, EMBASE, and Cochrane Library were searched for relevant studies up to Jan 1st, 2023. The meta-analysis mainly compared the outcome of the change in depression...
Clinical neuropsychiatry
October 1, 2023
Mario Miniati, Graziella Orrù, Mery Paroli et al.
7 citations
To investigate mindfulness traits/attitudes as protective factors against chronic pain related distress, depression and anxiety. Fifty patients (25 with chronic non-oncologic pain-NOP; 25 with chronic oncologic pain-COP) were administered with the following scales: Visual Analogue Scale (VAS), Pain Disability Index (PDI), Italian Questionnaire for Pain (QUID), Perceived Stress Scale (PSS),...